Lower Mortality and Complication Rates for Solid-Organ Transplant Patients Treated at Specialized Transplant Centers for Emergency General Surgery
Posted inEmergency Medicine General Surgery Nephrology news

Lower Mortality and Complication Rates for Solid-Organ Transplant Patients Treated at Specialized Transplant Centers for Emergency General Surgery

A large-scale retrospective study in Ontario indicates that solid-organ transplant recipients, particularly kidney transplant patients, experience significantly better outcomes for emergency general surgery conditions when treated at specialized transplant centers compared to academic or community hospitals.
Decoding Glycemic Control in Dialysis: Why HbA1c and Glycated Albumin Require a Nuanced Approach
Posted inDiabetes & Endocrinology Nephrology news

Decoding Glycemic Control in Dialysis: Why HbA1c and Glycated Albumin Require a Nuanced Approach

This study evaluates HbA1c, glycated albumin, and fructosamine against CGM in dialysis patients. While HbA1c and glycated albumin show strong correlations with mean glucose, significant clinical biases from ESA use, BMI, and dialysis modality necessitate cautious, individualized interpretation in clinical practice.
Intensive Blood Pressure Targets Below 130/80 mmHg Benefit Patients Across the Cardiovascular-Kidney-Metabolic Syndrome Spectrum
Posted inCardiology Nephrology news

Intensive Blood Pressure Targets Below 130/80 mmHg Benefit Patients Across the Cardiovascular-Kidney-Metabolic Syndrome Spectrum

A post hoc analysis of the CRHCP trial demonstrates that intensive blood pressure control (<130/80 mmHg) significantly reduces major adverse **Confirming JSON Structure** I'm now fully focused on creating the JSON object. I've re-reviewed both schemas, and am following the most up-to-date and complete instructions. I'm double-checking the required fields, especially `thumbnail`, `lang`, and `multilang`, to ensure the final output is perfectly structured and valid. cardiovascular events across CKM syndrome stages 2 through 4, providing a favorable net clinical benefit despite an increased risk of hypotension.
SGLT2 Inhibitors Provide Robust Kidney Protection Across All Stages of CKD and Levels of Albuminuria: Evidence from the SMART-C Meta-Analysis
Posted inDiabetes & Endocrinology Nephrology news

SGLT2 Inhibitors Provide Robust Kidney Protection Across All Stages of CKD and Levels of Albuminuria: Evidence from the SMART-C Meta-Analysis

A meta-analysis of over 70,000 participants confirms that SGLT2 inhibitors significantly reduce chronic kidney disease progression regardless of baseline kidney function or albuminuria levels, supporting their use even in patients with Stage 4 CKD or minimal protein excretion.